TuHURA Biosciences, Inc. (HURA)
NASDAQ: HURA · Real-Time Price · USD
2.050
0.00 (0.00%)
Sep 14, 2026, 4:00 PM EDT - Market closed
← View all transcripts

AGM 2026

Aug 18, 2026

Summary

The meeting covered director elections, share issuance, executive compensation, and auditor ratification, with all proposals approved by stockholders. No questions were raised, and the Board's recommended three-year frequency for compensation votes was adopted.

Operator

Hello, and welcome to the 2026 TuHURA Biosciences Inc. Annual Meeting of Stockholders. Please note that this meeting is being recorded. Questions may be submitted via the question box to the right of your screen by typing your message and then clicking the Submit button. Your meeting is now going to begin.

Jim Bianco
President and CEO, TuHURA Biosciences Inc

Good morning. I am Dr. Jim Bianco. I am the President and CEO of TuHURA Biosciences. I would like to welcome each of you to our 2026 Annual Meeting of the Stockholders, being held this year virtually by remote communication. I will serve as Chairman and Secretary of this annual meeting. It is now 9:01 A.M. Eastern Time, and the polls are open. Please note that the polls will close in several minutes, so we urge you to vote your shares now if you have not already submitted a proxy or otherwise voted. If you have already submitted your proxy, then you do not need to vote again.

As Secretary of the meeting, I will include with the minutes of this meeting a copy of the affidavit of distribution, certified list of stockholders, a notice of meeting, and the proxy statement, which we refer to as the proxy materials. The notice of meeting and proxy statement were filed with the Securities and Exchange Commission on July 9th, 2026, and mailed to stockholders on or about July 9th of 2026. The proxy statement describes the record date for this meeting and the number of eligible votes of common stock outstanding on that date. A

list of stockholders entitled to vote at this annual meeting has been available at TuHURA's headquarters since July 29th, 2026, and will remain available throughout this meeting for examination by any stockholder desiring to do so. Prior to the meeting, I appointed [Maritza Merced] as the Inspector of Election, and she has taken the appropriate oath. At this point, I will call the formal portion of our meeting to order. Will the Inspector of Elections please report on the existence of a quorum?

Speaker 3

The Board of Directors selected June 26th, 2026, as the record date for the annual meeting. On the record date, there were 63,682,528 shares of common stock of TuHURA outstanding. Proxies representing at least 1/3 of the voting power of TuHURA's issued and outstanding stock entitled to vote at the annual meeting have been received. Accordingly, the quorum is present.

Jim Bianco
President and CEO, TuHURA Biosciences Inc

Okay. Since a quorum is present, we may now proceed to do the business of the meeting. Following the presentation of the proposals and a brief question- and- answer session, if our stockholders have any questions specifically regarding the proposals, we will declare the polls closed and ask the Inspector of Election to provide a preliminary voting tally. The final results will be reported by TuHURA in a current report on a Form 8-K within four business days. The first proposal before the stockholders of TuHURA is the election of six directors to serve until the annual meeting of stockholders in 2027, and until their successors are duly elected and qualified, or until their earlier death, resignation, or removal. The Board has nominated and recommends the election of the following persons as directors of the company: James Bianco, James Manuso, Alan List, George Ng, Robert Hoffman, and Craig Tendler.

I'll refer to this proposal as the director nomination proposal. The second proposal relates to a vote to approve, in accordance with Nasdaq Listing Rule 5635, the issuance of 1,878,287 shares of common stock issuable to Parkview Holdings One LLC, an affiliate of our largest shareholder, Mr. Vijay Patel, pursuant to the terms of our revolving credit facility with Parkview, entered into in April 2026. I will refer to this proposal as the Nasdaq proposal. The third proposal relates to a vote to approve on an advisory, non-binding basis, the compensation of TuHURA's named executive officers. I will refer to this proposal as the executive compensation proposal.

The fourth proposal relates to a vote to approve on an advisory, non-binding basis, the frequency of future advisory votes on named executive officer compensation. I will refer to this proposal as the say on frequency proposal. The fifth proposal relates to ratifying the appointment of Cherry Bekaert LLP as TuHURA's independent registered public accounting firm for the fiscal year ending December 31st, 2026. I'll refer to this proposal as the auditor ratification proposal. The sixth proposal relates to a vote to adjourn this annual meeting to a later date or time if necessary, and I'll refer to this proposal as the adjournment proposal. I will now entertain and review any questions that stockholders have submitted through our online portal relating specifically to the proposals, if any.

Dan Dearborn
CFO, TuHURA Biosciences Inc

Jim, there are no questions.

Jim Bianco
President and CEO, TuHURA Biosciences Inc

Thank you, Dan. At this point, since there are no questions, I will end the question and comment period. At this time, we have received proxies from the company's stockholders offering us to vote shares on the items of business for this meeting, and we have voted these shares accordingly. It is now 9:06 A.M. Eastern Time, and since everyone has now had the chance to vote, I hereby declare that the polls are officially closed. The Inspector of Election will now report on the preliminary results of the proposals. Ms. Merced.

Speaker 3

Each of the director nominees named in the director nomination proposal has been approved by a plurality of the votes cast. The Nasdaq proposal has been approved by a majority of the votes cast. The executive compensation proposal has been approved by a majority of the votes cast. With respect to the say on frequency proposal, the Board's recommended frequency of every three years received the highest number of votes cast. The auditor ratification proposal has been approved by a majority of the votes cast. Because all other proposals have been approved, there was no need to vote on the adjournment proposal. The precise number of votes will be set forth in my written report.

Jim Bianco
President and CEO, TuHURA Biosciences Inc

Thank you. The Chair declares that the proposals have been approved. The certificate of the Inspector of Election with the final tabulation will be filed with the minutes of this meeting, and the proxies and the ballots will be filed with the corporate records, and the final results of each proposal will be disclosed in TuHURA's current report on a Form 8-K announcing the results of this annual meeting, which will be filed within four business days. That completes our official business agenda for today, and as such, I declare the meeting adjourned.

Operator

This concludes today's meeting. Thank you for participating, and you may now disconnect.